Graham Capital Management L.P. Buys 16,035 Shares of Genmab A/S Sponsored ADR $GMAB

Key Points

• Graham Capital Management L.P. increased its stake in Genmab A/S by 28.9%, acquiring an additional 16,035 shares for a total of 71,452 shares valued at approximately $1.4 million.
• Institutional investors have significantly increased their holdings in Genmab A/S, with Headlands Technologies raising its position by 1,525% to 1,560 shares during the first quarter.
• Genmab A/S reported earnings of $0.54 EPS for the last quarter, exceeding the consensus estimate of $0.39, while the company's stock has a Moderate Buy rating with an average price target of $37.60.

Graham Capital Management L.P. grew its stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 28.9% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 71,452 shares of the company's stock after acquiring an additional 16,035 shares during the period. Graham Capital Management L.P.'s holdings in Genmab A/S were worth $1,399,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Headlands Technologies LLC grew its position in shares of Genmab A/S by 1,525.0% during the 1st quarter. Headlands Technologies LLC now owns 1,560 shares of the company's stock valued at $31,000 after acquiring an additional 1,464 shares during the period. Caitong International Asset Management Co. Ltd grew its position in shares of Genmab A/S by 124.3% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company's stock valued at $38,000 after acquiring an additional 1,070 shares during the period. Barclays PLC grew its position in shares of Genmab A/S by 1,072.8% during the 4th quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after acquiring an additional 2,285 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Genmab A/S during the 4th quarter valued at approximately $60,000. Finally, Brooklyn Investment Group boosted its holdings in Genmab A/S by 729.3% in the 1st quarter. Brooklyn Investment Group now owns 4,246 shares of the company's stock worth $83,000 after buying an additional 3,734 shares during the period. 7.07% of the stock is owned by institutional investors.

Genmab A/S Price Performance

Shares of NASDAQ:GMAB opened at $25.89 on Wednesday. The firm has a fifty day moving average price of $22.41 and a two-hundred day moving average price of $21.34. Genmab A/S Sponsored ADR has a one year low of $17.24 and a one year high of $27.91. The company has a market cap of $16.61 billion, a price-to-earnings ratio of 13.01, a PEG ratio of 7.22 and a beta of 0.93.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.39 by $0.15. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. The firm had revenue of $925.00 million during the quarter, compared to the consensus estimate of $5.77 billion. Genmab A/S has set its FY 2025 guidance at EPS. Equities research analysts expect that Genmab A/S Sponsored ADR will post 1.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently commented on GMAB shares. Wall Street Zen raised shares of Genmab A/S from a "hold" rating to a "buy" rating in a report on Monday, July 28th. HC Wainwright raised their price objective on shares of Genmab A/S from $35.00 to $36.00 and gave the stock a "buy" rating in a report on Friday, August 15th. Truist Financial raised their price objective on shares of Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a report on Tuesday, July 8th. Finally, Zacks Research downgraded shares of Genmab A/S from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $37.60.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.